Skip to main content
SpringerLink
Log in

Current Management of Mantle Cell Lymphoma

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Mantle cell lymphoma is a rare yet well defined subtype of B-cell non-Hodgkin’s lymphoma. The correct histological diagnosis of this lymphoma subtype is of the utmost importance; however, it is also a very difficult diagnosis. Clinical management is often complex, and despite the successful introduction of monoclonal antibodies and dose-intensified regimens, including autologous and allogeneic stem cell transplantation strategies, the prognosis remains particularly poor. Recently gained insights into the underlying biology and pathogenesis have unravelled numerous promising molecular targeting strategies; however, their introduction into clinical practice and current treatment algorithms remains a challenge. This article addresses these issues providing relevant information for current state-of-the-art management of patients with mantle cell lymphoma and giving a perspective of upcoming treatment strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Table III
Fig. 2

Similar content being viewed by others

References

  1. Jaffe ES, Harris NL, Stein H. Tumours of the haemopoitic and lymphoid tissues. Lyon: IARC Press, 2001

    Google Scholar 

  2. Meusers P, Hense J, Brittinger G. Mantle cell lymphoma: diagnostic criteria, clinical aspects and therapeutic problems. Leukemia 1997; 11 Suppl. 2: S60–4

    PubMed  Google Scholar 

  3. Lenz G, Dreyling M, Hiddemann W. Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol 2004; 83(2): 71–7

    Article  PubMed  CAS  Google Scholar 

  4. Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005; 131(1): 29–38

    Article  PubMed  Google Scholar 

  5. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3(2): 185–97

    Article  PubMed  CAS  Google Scholar 

  6. Fernandez V, Hartmann E, Ott G, et al. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 2005; 23(26): 6364–9

    Article  PubMed  CAS  Google Scholar 

  7. Witzig TE. Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 2005; 23(26): 6409–14

    Article  PubMed  CAS  Google Scholar 

  8. Cohen PL, Kurtin PJ, Donovan KA, et al. Bone marrow and peripheral blood involvement in mantle cell lymphoma. Br J Haematol 1998; 101(2): 302–10

    Article  PubMed  CAS  Google Scholar 

  9. Romaguera JE, Medeiros LJ, Hagemeister FB, et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 2003; 97(3): 586–91

    Article  PubMed  Google Scholar 

  10. Oinonen R, Franssila K, Elonen E. Central nervous system involvement in patients with mantle cell lymphoma. Ann Hematol 1999; 78(3): 145–9

    Article  PubMed  CAS  Google Scholar 

  11. Montserrat E, Bosch F, Lopez-Guillermo A, et al. CNS involvement in mantle-cell lymphoma. J Clin Oncol 1996; 14(3): 941–4

    PubMed  CAS  Google Scholar 

  12. Chua SL, Seymour JF, Streater J, et al. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin’s lymphoma. Leuk Lymphoma 2002; 43(9): 1783–8

    Article  PubMed  CAS  Google Scholar 

  13. Weisenburger DD, Vose JM, Greiner TC, et al. Mantle cell lymphoma: a clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 2000; 64(3): 190–6

    Article  PubMed  CAS  Google Scholar 

  14. Khouri IF, Saliba RM, Okoroji GJ, et al. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer 2003; 98(12): 2630–5

    Article  PubMed  Google Scholar 

  15. Raty R, Franssila K, Joensuu H, et al. Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol 2002; 69(1): 11–20

    Article  PubMed  Google Scholar 

  16. Pott C, Schrader C, Gesk S, et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 2006; 107(6): 2271–8

    Article  PubMed  CAS  Google Scholar 

  17. Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20(5): 1288–94

    Article  PubMed  CAS  Google Scholar 

  18. Leitch HA, Gascoyne RD, Chhanabhai M, et al. Limited-stage mantle-cell lymphoma. Ann Oncol 2003; 14(10): 1555–61

    Article  PubMed  CAS  Google Scholar 

  19. M’Kacher R, Bennaceur A, Farace F, et al. Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphoma. Oncogene 2003; 22(39): 7905–12

    Article  PubMed  Google Scholar 

  20. Meusers P, Engelhard M, Bartels H, et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol 1989; 7(5): 365–80

    Article  PubMed  CAS  Google Scholar 

  21. Zucca E, Roggero E, Pinotti G, et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995; 6(3): 257–62

    PubMed  CAS  Google Scholar 

  22. Lenz G, Hiddemann W, Dreyling M. The role of fludarabine in the treatment of follicular and mantle cell lymphoma. Cancer 2004; 101(5): 883–93

    Article  PubMed  CAS  Google Scholar 

  23. Rummel MJ, Chow KU, Karakas T, et al. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin’s lymphoma. Eur J Cancer 2002; 38(13): 1739–46

    Article  PubMed  CAS  Google Scholar 

  24. Zinzani PL, Magagnoli M, Moretti L, et al. Fludarabine-based chemotherapy in untreated mantle cell lymphomas: an encouraging experience in 29 patients. Haematologica 1999; 84(11): 1002–6

    PubMed  CAS  Google Scholar 

  25. Zinzani PL, Magagnoli M, Moretti L, et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol 2000; 18(4): 773–9

    PubMed  CAS  Google Scholar 

  26. Seymour JF, Grigg AP, Szer J, et al. Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin’s lymphoma. Cancer 2002; 94(3): 585–93

    Article  PubMed  CAS  Google Scholar 

  27. Thomas DW, Owen RG, Johnson SA, et al. Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP. Leuk Lymphoma 2005; 46(4): 549–52

    Article  PubMed  CAS  Google Scholar 

  28. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104(10): 3064–71

    Article  PubMed  CAS  Google Scholar 

  29. Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 2000; 96(1): 71–5

    PubMed  CAS  Google Scholar 

  30. Cohen BJ, Moskowitz C, Straus D, et al. Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 2001; 42(5): 1015–22

    Article  PubMed  CAS  Google Scholar 

  31. Herold M, Schulze A, Niederwieser D, et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO#19). J Cancer Res Clin Oncol 2006; 132(2): 105–12

    Article  PubMed  CAS  Google Scholar 

  32. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol 2005; 23(15): 3383–9

    Article  PubMed  CAS  Google Scholar 

  33. Weide R, Heymanns J, Thomalla J, et al. Bendamustine/mitoxantrone/rituximab (BMR): a very effective and well tolerated immuno-chemotherapy for relapsed and refractory indolent lymphomas: high response rate in patients pretreated with rituximab. Results of a multicentre phase-II-study of the German Low Grade Lymphoma Study Group (GLSG) [abstract no. 6616]. 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 13–17; Orlando (FL). Proc Annu Meet Am Soc Clin Oncol 2005; 23(16s): 589s

    Google Scholar 

  34. Lefrere F, Delmer A, Suzan F, et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002; 16(4): 587–93

    Article  PubMed  CAS  Google Scholar 

  35. Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998; 16(12): 3803–9

    PubMed  CAS  Google Scholar 

  36. de Guibert S, Jaccard A, Bernard M, et al. Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma. Haematologica 2006; 91(3): 425–6

    PubMed  Google Scholar 

  37. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23(28): 7013–23

    Article  PubMed  CAS  Google Scholar 

  38. Ketterer N, Salles G, Espinouse D, et al. Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. Ann Oncol 1997; 8(7): 701–4

    Article  PubMed  CAS  Google Scholar 

  39. Stewart DA, Vose JM, Weisenburger DD, et al. The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Oncol 1995; 6(3): 263–6

    PubMed  CAS  Google Scholar 

  40. Freedman AS, Neuberg D, Gribben JG, et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol 1998; 16(1): 13–8

    PubMed  CAS  Google Scholar 

  41. Haas R, Brittinger G, Meusers P, et al. Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma. Leukemia 1996; 10(12): 1975–9

    PubMed  CAS  Google Scholar 

  42. Blay JY, Sebban C, Surbiguet C, et al. High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin’s lymphomas: a single center experience on 18 patients. Bone Marrow Transplant 1998; 21(1): 51–4

    Article  PubMed  CAS  Google Scholar 

  43. Kroger N, Hoffknecht M, Dreger P, et al. Long-term diseasefree survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy. Bone Marrow Transplant 1998; 21(1): 55–7

    Article  PubMed  CAS  Google Scholar 

  44. Dreger P, Martin S, Kuse R, et al. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients. Hematol J 2000; 1(2): 87–94

    Article  PubMed  CAS  Google Scholar 

  45. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105(7): 2677–84

    Article  PubMed  CAS  Google Scholar 

  46. Buske C, Weigert O, Dreyling M, et al. Current status and perspective of antibody therapy in follicular lymphoma. Haematologica 2006; 91(1): 104–12

    PubMed  CAS  Google Scholar 

  47. Ghielmini M, Schmitz SF, Cogliatti S, et al. Effect of singleagent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23(4): 705–11

    Article  PubMed  CAS  Google Scholar 

  48. Morschhauser F, Leonard J, Coiffier B, et al. Initial safety and efficacy results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in non-Hodgkin’s lymphoma [abstract]. Blood 2005; 106(11): 683a

    Google Scholar 

  49. Leonard JP, Coleman M, Ketas J, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol 2005; 23(22): 5044–51

    Article  PubMed  CAS  Google Scholar 

  50. DiJoseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 2004; 103(5): 1807–14

    Article  PubMed  CAS  Google Scholar 

  51. Younes A, Hariharan K, Allen RS, et al. Initial trials of antiCD80 monoclonal antibody (Galiximab) therapy for patients with relapsed or refractory follicular lymphoma. Clin Lymphoma 2003; 3(4): 257–9

    Article  PubMed  CAS  Google Scholar 

  52. Nagy ZA, Hubner B, Lohning C, et al. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat Med 2002; 8(8): 801–7

    PubMed  CAS  Google Scholar 

  53. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23(9): 1984–92

    Article  PubMed  CAS  Google Scholar 

  54. Herold M, Dolken G, Fiedler F, et al. Randomized phase III study for the treatment of advanced indolent non-Hodgkin’s lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab. Ann Hematol 2003; 82(2): 77–9

    PubMed  CAS  Google Scholar 

  55. Hiddemann W, Forstpointner R, Dreyling M, et al. Rituximab maintenance prolongs response duration after salvage therapy with R-FCM in patients with relapsed follicular lymphomas and mantle cell lymphomas: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) [abstract]. Blood (ASH Annual Meeting Abstracts) 2005; 106(11): 920

    Google Scholar 

  56. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108(13): 4003–8

    Article  PubMed  CAS  Google Scholar 

  57. Kahl B, Longo W, Eickhoff J, et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol 2006; 17(9): 1418–23

    Article  PubMed  CAS  Google Scholar 

  58. Schulz H, Bohlius J, Skoetz N, et al. Combined immunochemotherapy with rituximab improves overall survival in patients with follicular and mantle cell lymphoma: updated meta-analysis results. Blood 2006; 106(11): 106–7a

    Google Scholar 

  59. Gianni AM, Magni M, Martelli M, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003; 102(2): 749–55

    Article  PubMed  CAS  Google Scholar 

  60. Mangel J, Leitch HA, Connors JM, et al. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol 2004; 15(2): 283–90

    Article  PubMed  CAS  Google Scholar 

  61. Thieblemont C, Antal D, Lacotte-Thierry L, et al. Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer 2005; 104(7): 1434–41

    Article  PubMed  CAS  Google Scholar 

  62. European MCL Network [online]. Available from URL: http://www.European-MCL.nets [Accessed 2007 May 30]

  63. Johansson L, Carlsson J, Nilsson K. Radiosensitivity of human B-lymphocytic lymphomas in vitro. Int J Radiat Biol Relat Stud Phys Chem Med 1982; 41(4): 411–20

    Article  PubMed  CAS  Google Scholar 

  64. Safwat A. The role of low-dose total body irradiation in treatment of non-Hodgkin’s lymphoma: a new look at an old method. Radiother Oncol 2000; 56(1): 1–8

    Article  PubMed  CAS  Google Scholar 

  65. Press OW. Radioimmunotherapy for non-Hodgkin’s lymphomas: a historical perspective. Semin Oncol 2003; 30 (2 Suppl. 4): 10–21

    Article  PubMed  CAS  Google Scholar 

  66. Anderson KC, Bates MP, Slaughenhoupt BL, et al. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984; 63(6): 1424–33

    PubMed  CAS  Google Scholar 

  67. Press OW, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987; 69(2): 584–91

    PubMed  CAS  Google Scholar 

  68. Tedder TF, Boyd AW, Freedman AS, et al. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 1985; 135(2): 973–9

    PubMed  CAS  Google Scholar 

  69. Rao AV, Akabani G, Rizzieri DA. Radioimmunotherapy for non-Hodgkin’s lymphoma. Clin Med Res 2005; 3(3): 157–65

    Article  PubMed  CAS  Google Scholar 

  70. Younes A, Pro B, Rodriguez MA, et al. Activity of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) in 22 patients with relapsed and refractory mantle cell lymphoma (MCL) [abstract no. 2452]. Blood 2005; 106(11): 689a

    Google Scholar 

  71. Weigert O, Schilling C, Rummel MJ, et al. Efficacy and safety of a single-course of yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin®) in patients with relapsed or refractory mantle cell lymphoma (MCL) after/not appropriate for autologous stem cell transplantation (ASCT): a phase II trial of the European MCL Network [abstract no. 4786]. Blood 2005; 106(11): 277b

    Google Scholar 

  72. Zelenetz A, Noy A, Pandit-Taskar N, et al. Sequential radioimmunotherapy with tositumomab/iodine 1131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions [abstract]. Proc Am Soc Clin Oncol 2006; 24(18S): 436s

    Google Scholar 

  73. Weigert O, Jurczak W, Schilling C, et al. Efficacy of radioimmunotherapy with (90Y) ibritumomab tiuxetan is superior as consolidation in relapsed or refractory mantle cell lymphoma: results of two phase II trials of the European MCL Network and the PLRG [abstract]. Proc Am Soc Clin Oncol 2006; 24(18S): 430s

    Google Scholar 

  74. Devizzi L, Seregni E, Guidetti A, et al. High-dose myeloablative Zevalin radioimmunotherapy with tandem stem-cell autografting has minimal toxicity and full feasibility in an outpatient setting [abstract]. Blood 2005; 106(11): 768a

    Google Scholar 

  75. Shimoni A, Zwas T, Oksman Y, et al. Ibritumomab tiuxetan (Zevalin) in the conditioning regimen for autologous and reduced-intensity allogeneic stem-cell transplantation in patients with chemo-refractory non-Hodgkin’s lymphoma [abstract no. 1131]. Blood 2005; 106(11): 329a

    Google Scholar 

  76. Gopal AK, Rajendran JG, Petersdorf SH, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99(9): 3158–62

    Article  PubMed  CAS  Google Scholar 

  77. Martinez N, Camacho FI, Algara P, et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res 2003; 63(23): 8226–32

    PubMed  CAS  Google Scholar 

  78. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5(4): 297–309

    Article  PubMed  CAS  Google Scholar 

  79. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994; 79: 13–21

    Article  PubMed  CAS  Google Scholar 

  80. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4(5): 349–60

    Article  PubMed  CAS  Google Scholar 

  81. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348(26): 2609–17

    Article  PubMed  CAS  Google Scholar 

  82. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352(24): 2487–98

    Article  PubMed  CAS  Google Scholar 

  83. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20(22): 4420–7

    Article  PubMed  CAS  Google Scholar 

  84. O’Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23(4): 676–84

    Article  PubMed  Google Scholar 

  85. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2005; 23(4): 667–75

    Article  PubMed  CAS  Google Scholar 

  86. Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006; 24(13): 2105–12

    Article  PubMed  CAS  Google Scholar 

  87. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. I Clin Oncol 2006; 24(30): 4867–74

    Article  Google Scholar 

  88. leremias I, Kupatt C, Baumann B, et al. Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood 1998; 91(12): 4624–31

    Google Scholar 

  89. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101(6): 2377–80

    Article  PubMed  CAS  Google Scholar 

  90. Leonard J, Furman R, Cheung Y-K, et al. Phase I/II trial of bortezomib + CHOP-rituximab in diffuse large B cell (DLBCL) and mantle cell lymphoma (MCL): phase I results [abstract]. Blood 2005; 106(11): 147a

    Google Scholar 

  91. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105(8): 3058–65

    Article  PubMed  CAS  Google Scholar 

  92. Weigert O, Pastore A, Rieken M, et al. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia 2007; 21(3): 524–8

    Article  PubMed  CAS  Google Scholar 

  93. Kaufmann H, Raderer M, Wohrer S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004; 104(8): 2269–71

    Article  PubMed  CAS  Google Scholar 

  94. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of singleagent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23(23): 5347–56

    Article  PubMed  CAS  Google Scholar 

  95. Ansell SM, Geyer SM, Kurtin P, et al. Anti-tumor activity of mTOR inhibitor temsirolimus for relapsed mantle cell lymphoma: a phase II trial in the North Central Cancer Treatment Group [abstract]. Proc Am Soc Clin Oncol 2006; 24(18s): 430s

    Google Scholar 

  96. Kouroukis CT, Belch A, Crump M, et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21(9): 1740–5

    Article  PubMed  CAS  Google Scholar 

  97. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109(2): 399–404

    Article  PubMed  CAS  Google Scholar 

  98. Kroger N, Hoffknecht M, Kruger W, et al. Allogeneic bone marrow transplantation for refractory mantle cell lymphoma. Ann Hematol 2000; 79(10): 578–80

    Article  PubMed  CAS  Google Scholar 

  99. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003; 21(23): 4407–12

    Article  PubMed  CAS  Google Scholar 

  100. Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100(13): 4310–6

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. Dr Unterhalt has no conflicts of interest that are directly relevant to the content of this review. Dr Weigert has received speaker’s honoraria from Roche and Schering. Dr Hiddemann has acted as a consultant and provided expert testimony for Roche, received speaker’s honoraria from Roche and Schering, and received financial support for investigator initiated clinical trials from Roche, Schering and Millenium. Dr Dreyling has acted as a consultant for Millenium, received speaker’s honoraria from Roche and Schering, and received financial support for clinical trials from Roche, Schering and OrthoBiotech.

Author information

Authors and Affiliations

  1. Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University, Marchioninistrasse 15, Munich, 81377, Germany

    Oliver Weigert, Michael Unterhalt, Wolfgang Hiddemann & Martin Dreyling

Authors
  1. Oliver Weigert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Unterhalt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wolfgang Hiddemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Martin Dreyling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Oliver Weigert.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weigert, O., Unterhalt, M., Hiddemann, W. et al. Current Management of Mantle Cell Lymphoma. Drugs 67, 1689–1702 (2007). https://doi.org/10.2165/00003495-200767120-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200767120-00004

Keywords

Search

Navigation